These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33104796)

  • 1. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase.
    Mascarenhas JO; Rampal RK; Kosiorek HE; Bhave R; Hexner E; Wang ES; Gerds A; Abboud CN; Kremyanskaya M; Berenzon D; Odenike O; Farnoud N; Krishnan A; Weinberg RS; McGovern E; Salama ME; Najfeld V; Medina-Martinez JS; Arango Ossa JE; Levine MF; Zhou Y; Sandy L; Heaney ML; Levine RL; Mesa RA; Dueck AC; Hoffman R
    Blood Adv; 2020 Oct; 4(20):5246-5256. PubMed ID: 33104796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
    Rampal RK; Mascarenhas JO; Kosiorek HE; Price L; Berenzon D; Hexner E; Abboud CN; Kremyanskaya M; Weinberg RS; Salama ME; Menghrajani K; Najfeld V; Sandy L; Heaney ML; Levine RL; Mesa RA; Dueck AC; Goldberg JD; Hoffman R
    Blood Adv; 2018 Dec; 2(24):3572-3580. PubMed ID: 30563881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms.
    Zhou S; Tremblay D; Hoffman R; Kremyanskaya M; Najfeld V; Li L; Moshier E; Mascarenhas J
    Acta Haematol; 2021; 144(1):48-57. PubMed ID: 32160610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
    Badar T; Kantarjian HM; Ravandi F; Jabbour E; Borthakur G; Cortes JE; Pemmaraju N; Pierce SR; Newberry KJ; Daver N; Verstovsek S
    Leuk Res; 2015 Sep; 39(9):950-6. PubMed ID: 26183878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy.
    Handa S; Sivakumar G; Srisuwananukorn A; Dueck A; Tremblay D; Mascarenhas JO; Ginzburg Y; Kremyanskaya M; Hoffman R
    Clin Lymphoma Myeloma Leuk; 2024 Sep; 24(9):e314-e319. PubMed ID: 38839448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
    Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
    Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms.
    Mannelli F; Guglielmelli P; Fazi P; Crea E; Piciocchi A; Vignetti M; Amadori S; Pane F; Venditti A; Vannucchi AM
    Future Oncol; 2023 Jan; 19(2):103-111. PubMed ID: 36651780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
    Systchenko T; Chomel JC; Gallego-Hernanz P; Moya N; Desmier D; Maillard N; Bobin A; Vonfeld M; Gardeney H; Cayssials E E; Torregrosa J
    Br J Haematol; 2023 Jul; 202(2):284-288. PubMed ID: 37183377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis.
    Chen J; Wang K; Xiao Z; Xu Z
    Ann Med; 2023 Dec; 55(1):348-360. PubMed ID: 36644935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
    Andriani A; Elli E; Trapè G; Villivà N; Fianchi L; Di Veroli A; Niscola P; Centra A; Anaclerico B; Montanaro G; Martini V; Aroldi A; Carmosino I; Voso MT; Breccia M; Montanaro M; Foà R; Latagliata R
    Hematol Oncol; 2019 Aug; 37(3):291-295. PubMed ID: 31050810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
    Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
    Jabbour E; Short NJ; Montalban-Bravo G; Huang X; Bueso-Ramos C; Qiao W; Yang H; Zhao C; Kadia T; Borthakur G; Pemmaraju N; Sasaki K; Estrov Z; Cortes J; Ravandi F; Alvarado Y; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Kantarjian H; Garcia-Manero G
    Blood; 2017 Sep; 130(13):1514-1522. PubMed ID: 28774880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
    Kadia TM; Cortes J; Ravandi F; Jabbour E; Konopleva M; Benton CB; Burger J; Sasaki K; Borthakur G; DiNardo CD; Pemmaraju N; Daver N; Ferrajoli A; Wang X; Patel K; Jorgensen JL; Wang S; O'Brien S; Pierce S; Tuttle C; Estrov Z; Verstovsek S; Garcia-Manero G; Kantarjian H
    Lancet Haematol; 2018 Sep; 5(9):e411-e421. PubMed ID: 30115541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.
    Short NJ; Kantarjian HM; Loghavi S; Huang X; Qiao W; Borthakur G; Kadia TM; Daver N; Ohanian M; Dinardo CD; Estrov Z; Kanagal-Shamanna R; Maiti A; Benton CB; Bose P; Alvarado Y; Jabbour E; Kornblau SM; Pemmaraju N; Jain N; Gasior Y; Richie MA; Pierce S; Cortes J; Konopleva M; Garcia-Manero G; Ravandi F
    Lancet Haematol; 2019 Jan; 6(1):e29-e37. PubMed ID: 30545576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
    Eghtedar A; Verstovsek S; Estrov Z; Burger J; Cortes J; Bivins C; Faderl S; Ferrajoli A; Borthakur G; George S; Scherle PA; Newton RC; Kantarjian HM; Ravandi F
    Blood; 2012 May; 119(20):4614-8. PubMed ID: 22422826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
    Oki Y; Kantarjian HM; Gharibyan V; Jones D; O'brien S; Verstovsek S; Cortes J; Morris GM; Garcia-Manero G; Issa JP
    Cancer; 2007 Mar; 109(5):899-906. PubMed ID: 17236224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).
    Roboz GJ; Mandrekar SJ; Desai P; Laumann K; Walker AR; Wang ES; Kolitz JE; Powell BL; Attar EC; Stock W; Bloomfield CD; Kohlschmidt J; Mrózek K; Hassane DC; Garraway L; Jané-Valbuena J; Baltay M; Tracy A; Marcucci G; Stone RM; Larson RA
    Blood Adv; 2018 Dec; 2(24):3608-3617. PubMed ID: 30567725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
    Assi R; Kantarjian HM; Garcia-Manero G; Cortes JE; Pemmaraju N; Wang X; Nogueras-Gonzalez G; Jabbour E; Bose P; Kadia T; Dinardo CD; Patel K; Bueso-Ramos C; Zhou L; Pierce S; Gergis R; Tuttle C; Borthakur G; Estrov Z; Luthra R; Hidalgo-Lopez J; Verstovsek S; Daver N
    Am J Hematol; 2018 Feb; 93(2):277-285. PubMed ID: 29134664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
    Abaza Y; Kantarjian H; Alwash Y; Borthakur G; Champlin R; Kadia T; Garcia-Manero G; Daver N; Ravandi F; Verstovsek S; Burger J; Estrov Z; Ohanian M; Lim M; Pemmaraju N; Jabbour E; Cortes J
    Am J Hematol; 2020 Nov; 95(11):1288-1295. PubMed ID: 32681739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.